2008
Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants
Görk A, Ehrenkranz R, Bracken M. Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. 2008, 2010: cd006071. PMID: 18254092, PMCID: PMC8912238, DOI: 10.1002/14651858.cd006071.pub2.Peer-Reviewed Original ResearchConceptsSymptomatic patent ductus arteriosusPatent ductus arteriosusTreatment of PDAContinuous indomethacin infusionRetinopathy of prematurityPDA closurePreterm infantsBolus administrationBolus injectionBlood flowBronchopulmonary dysplasiaIndomethacin infusionIntraventricular hemorrhagePremature infantsContinuous infusionMesenteric circulationRelative riskRisk differencePatent ductus arteriosus closureCerebral blood flow velocityAdverse effectsCochrane Neonatal reviewsContinuous infusion groupIntermittent bolus dosesSymptomatic preterm infants
1994
Clinically useful measures of effect in binary analyses of randomized trials
Sinclair J, Bracken M. Clinically useful measures of effect in binary analyses of randomized trials. Journal Of Clinical Epidemiology 1994, 47: 881-889. PMID: 7730891, DOI: 10.1016/0895-4356(94)90191-0.Peer-Reviewed Original ResearchConceptsOdds ratioTreatment effectsHigher baseline riskRelative risk reductionRandomized clinical trialsControl group risksGroups of trialsLarge treatment effectsPhysician appreciationRandomized trialsRisk ratioClinical trialsRelative riskBaseline riskTreatment decisionsClinical questionsRisk differenceTrialsSingle trialRisk reductionRiskGroup riskPhysiciansAbsolute effectUseful measure